Hi

Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-lin
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论2

  • 推荐
  • 最新
empty
暂无评论